Moxonidine-in mild to moderate systemic hypertension

We have recently concluded a nation wide post marketing study on efficacy and safety of Moxonidine in mild to moderate hypertensives. In all 97 patients were enrolled and out of these 87 completed a 12 weeks trial. There was an average drop of 12.9 mmHg in the DBP and 16.5 mmHg in SBP. 80% patient required a daily dose of 0.2 - 0.4 mg of Moxonidine for control of their BP In 84% of the patients completing the trial the BP changed from moderate to mild or normal or from mild toonormal. The drug was well tolerated, only 2.3% having adverse effects. We conclude that the drug studied is an effective alternate for the control of hypertension